Severe pain is present in about three-quarters of the millions who suffer from cancer or HIV/AIDS in developing countries. Opioids, especially morphine, are vital for pain relief, yet western European countries -in contrast to those in eastern Europe -account for 88% of the total European consumption of opioids. Eighty per cent of the world's population live in developing countries but receive only 6% of the available morphine. Pain control is possible using World Health Organization (WHO) guidelines in 85-90% of cancer patients, but far fewer gain relief as a result of several barriers to treatment, including inadequate training of healthcare professionals in pain management, obstructions due to governmental health regulations, fear of opioid addiction in health professionals, government advisors and the general public and, in some cases, the costs of medication. The position is similar for HIV/AIDS sufferers.
In economically developed countries, chronic pain affects about 20%
of the adult population, of which those with cancer account for Evidence from the wide range of treatments used for cancer pain shows that in 85-90% of patients the pain can be controlled using the WHO Supportive Oncology
obstructions posed by government health regulations, a fear of opioid addiction and, in some countries, the cost of medication. There remains clear evidence that barriers to treatment are much greater in some regions of the world than in others, especially in developing countries.
For example, in an International Narcotics Control Board report it was revealed that in Europe, 10 western countries accounted for 88% of the total consumption of opioids. Therefore, despite the fact that morphine is a drug included in the WHO model of essential drugs, people in eastern Europe are undertreated. 6 Moreover, given that over 80% of the world's population lives in developing countries, it is shameful that they receive only 6% of the morphine available.
Members of IASP in 10 eastern European countries, from a total of 46 developing countries in the association, contributed to an IASP survey of cancer treatment and the availability of opioids. 7 This gave a clear indication of the availability of this group of drugs in contrast to the extent to which patients receive them for the treatment of severe pain.
Overall, the availability of opioids was high, with 93% of respondents reporting that morphine was available, with figures for fentenyl at 73%, methadone at 56% and weak opioids at 89%. Respondents from eastern
European countries followed this reporting pattern. However, overall 36% of respondents reported that only 50% or more patients received opioids, 52% reported figures of 10-50% and 12% reported that fewer than 10% of patients received opioid drugs. The figures from eastern Europe were 37.5, 58.3 and 4.2%, respectively. The lowest levels of availability in the study were in the African regions and the Indian subcontinent, revealing a worldwide treatment gap between economically developed and developing countries.
An IASP publication in 1996 by Breitbart and others commented that undertreatment of pain was more widespread in AIDS than in cancer. 
